David Fredrickson - AstraZeneca PLC President
| AZN Stock | USD 64.26 1.06 1.68% |
President
Mr. David Fredrickson is Executive Vice President, Global Head Oncology Business Unit of the Company. He was appointed Executive VicePresident, Global Head Oncology Business in October 2017 and is responsible for driving growth and maximising the commercial performance of the global oncology and haematology portfolio. In addition, he plays a critical leadership role in setting the Oncology portfolio and product strategy for the organisation. Previously, Dave served as President of AstraZeneca K.K. in Japan, and VicePresident, Specialty Care in the US, spanning oncology, infectious disease, and neuroscience medicines. Dave joined AstraZeneca from RocheGenentech in 2014, where he was Business Unit Manager, Oncology in Spain and held growing commercial responsibilities in strategy, marketing and sales in the US. He also served for nine years at the Monitor Group, LLC, a global strategy consultancy. He has served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a member of the Board of the Japan Pharmaceutical Manufacturers Association . He is a graduate of Georgetown University in Government. since 2017.
| Tenure | 7 years |
| Address | 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has Return on Asset of 0.085 % which means that on every $100 spent on assets, it made $0.085 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1666 %, implying that it generated $0.1666 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Assets is likely to grow to 0.10, while Return On Tangible Assets are likely to drop 0.11. At this time, AstraZeneca PLC's Return On Assets are very stable compared to the past year. As of the 22nd of November 2024, Asset Turnover is likely to grow to 0.79, while Total Current Assets are likely to drop about 15.3 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Greg Yorston | Gfl Environmental Holdings | 60 | |
| Rob Rebel | Knife River | N/A | |
| Richard Early | Gfl Environmental Holdings | N/A | |
| Brett Mattison | Gold Fields Ltd | 41 | |
| Luke Pelosi | Gfl Environmental Holdings | 43 | |
| Askar Tashtitov | Freedom Holding Corp | 45 | |
| Avishkar Nagaser | Gold Fields Ltd | 41 | |
| Luis Rivera | Gold Fields Ltd | 54 | |
| Richard Butcher | Gold Fields Ltd | 56 | |
| Gregory Yorston | Gfl Environmental Holdings | 56 | |
| Jeffrey Thiede | Knife River | 62 | |
| Taryn Harmse | Gold Fields Ltd | 47 | |
| Christian Dover | Gfl Environmental Holdings | 41 | |
| Edward Glavina | Gfl Environmental Holdings | 58 | |
| Craig Orenstein | Gfl Environmental Holdings | N/A | |
| Peter Fasolo | Johnson Johnson | 61 | |
| Naseem Chohan | Gold Fields Ltd | 59 | |
| Julie Boudreau | Gfl Environmental Holdings | N/A | |
| James Swanson | Johnson Johnson | 58 | |
| Brad Arntson | Knife River | N/A | |
| Joseph Wolk | Johnson Johnson | 54 | |
Management Performance
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.085 |
AstraZeneca PLC ADR Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, Chief Financial Officer, Executive Director | ||
| Sherilyn McCoy, Non-Executive Independent Director | ||
| Genevieve Berger, Non-Executive Independent Director | ||
| Nazneen Rahman, Non-Executive Independent Director | ||
| Jose Baselga, Executive Vice President - Research & Development Oncology | ||
| Deborah Eldracher, Non-Executive Independent Director | ||
| Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance Officer | ||
| Tony Mok, Non-Executive Independent Director | ||
| Fiona Cicconi, Executive Vice President - Human Resources | ||
| Deborah DiSanzo, Non-Executive Independent Director | ||
| Chris Sheldon, Head Relations | ||
| Leif Johansson, Non-Executive Independent Chairman of the Board | ||
| Leon Wang, Executive Vice President - International and China President | ||
| Adrian Kemp, Company Secretary | ||
| Susan MD, Executive Development | ||
| Michel Demare, Non-Executive Independent Director | ||
| Graham Chipchase, Senior Non-Executive Independent Director | ||
| Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee | ||
| Pam Cheng, Executive Vice-President of Operations and Information Technology | ||
| MBA DVM, CEO Director | ||
| Aradhana MD, CFO Director | ||
| Philip Broadley, Non-Executive Independent Director | ||
| Jeffrey Pott, General Counsel | ||
| Ruud Dobber, Executive Vice President, BioPharmaceuticals Business | ||
| David Fredrickson, Executive Vice-President Global Head Oncology Business Unit | ||
| Jeffrey JD, Chief CHRO | ||
| Gonzalo Vina, Head Relations | ||
| Andrew Barnett, Head Relations | ||
| Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticals | ||
| Marcus Wallenberg, Non-Executive Director | ||
| Iskra Reic, Executive Vice President - Europe and Canada |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | ||||
| Return On Asset | 0.085 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 222.82 B | ||||
| Shares Outstanding | 3.1 B | ||||
| Shares Owned By Institutions | 16.75 % | ||||
| Number Of Shares Shorted | 4.63 M | ||||
| Price To Earning | 103.39 X | ||||
| Price To Book | 4.81 X |
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving together with AstraZeneca Stock
Moving against AstraZeneca Stock
| 0.81 | VERA | Vera Therapeutics | PairCorr |
| 0.73 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.71 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.68 | DVAX | Dynavax Technologies | PairCorr |
| 0.64 | DSGN | Design Therapeutics | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.034 | Dividend Share 2.97 | Earnings Share 2.07 | Revenue Per Share 2.7424 | Quarterly Revenue Growth 0.18 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.